Polyrizon Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PLRZ Nasdaq 2836 www.polyrizon-biotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Polyrizon Ltd.

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker - Sep 22nd, 2026 6:33 am
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement - Sep 4th, 2026 9:58 am
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement - Sep 3rd, 2026 6:50 am
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study - Sep 2nd, 2026 5:32 am
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment - Aug 20th, 2026 7:30 am
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Jul 2nd, 2026 6:29 am
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - Jul 2nd, 2026 5:32 am
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - Jun 29th, 2026 6:44 am
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - Jun 17th, 2026 6:15 am
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - Jun 15th, 2026 6:05 am
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - Jun 10th, 2026 5:47 am
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial - Jun 8th, 2026 7:25 am
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial - May 13th, 2026 7:25 am
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform - May 4th, 2026 6:45 am
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements - Apr 8th, 2026 2:16 pm
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement - Apr 7th, 2026 6:00 am
Polyrizon Provides 2025 and Recent Highlights - Mar 26th, 2026 7:23 am
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - Mar 25th, 2026 3:25 pm
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications - Mar 24th, 2026 6:47 am